Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Johnson and Johnson
Harvard Business School
Baxter
Colorcon

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

BETASERON Drug Profile

See Plans and Pricing

« Back to Dashboard

US Patents for BETASERON

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   See Pricing Schutzer; Steven E. (New York, NY) 2033-08-15 RX Orphan search
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   See Pricing MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX Orphan search
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   See Pricing Preciflex SA (Biel/Bienne, CH) 2031-07-25 RX Orphan search
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   See Pricing Rani Therapeutics, LLC (San Jose, CA) 2030-12-23 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for BETASERON

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300845 Netherlands   See Pricing PRODUCT NAME: DADIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160705
C 2016 046 Romania   See Pricing PRODUCT NAME: DACLIZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1107; DATE OF NATIONAL AUTHORISATION: 20160701; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1107; DATE OF FIRST AUTHORISATION IN EEA: 20160701
C01539200/01 Switzerland   See Pricing PRODUCT NAME: DACLIZUMAB BETA; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 66069 26.01.2017
55/2016 Austria   See Pricing PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 (MITTEILUNG) 20160705
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
McKesson
Colorcon
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.